ABSTRACT
(OR 0.47, P < 0.001) and sweating (OR 0.61, P = 0.01) than those in the bicalutamide group.
The time course of FACT-P scores showed no inter-group differences.
Conclusions:
Our results suggest that CAB using a steroidal antiandrogen such as chlormadinone may induce fewer and less distressing hot flashes than CAB with bicalutamide.
INTRODUCTION
A hot flash is a sudden, temporary onset of body warmth and may be accompanied by flushing and sweating. Hot flashes are the most common symptom in menopausal women and are also a common and potentially chronic problem in men with prostate cancer who undergo androgen deprivation therapy (ADT). 1 Up to 80% of patients treated with a luteinizing hormone-releasing hormone (LHRH) agonist report hot flashes, and up to 27% report this as the most troublesome adverse effect. 2 Hot flashes can significantly affect quality of life (QOL) for men undergoing ADT. However, the characteristics of hot flashes in men undergoing ADT have not been widely studied. 1 Methods to avoid or reduce these unpleasant side effects as much as possible have been investigated. In particular, the hot flash-preventive and -improving effects of steroidal antiandrogens have been reported. 3, 4 Chlormadinone acetate (chlormadinone), which we used in the present study, is a steroidal antiandrogen that is used in combined androgen blockade (CAB) therapy as well as monotherapy for prostate cancer in Japan. A double-blind controlled study 5 has verified the therapeutic equivalence of bicalutamide and chlormadinone.
Based on the above background, we conducted the present prospective, randomized study to longitudinally examine the status of the development of hot flashes in and QOL of Japanese 6 patients with prostate cancer who underwent CAB with a steroidal or nonsteroidal antiandrogen. Cancer Therapy-Prostate (FACT-P), 7 the validity of which has been verified, was used to evaluate QOL of the patients. Hot flashes and QOL were evaluated according to the self-administered system. Timing for survey was as follows: at baseline; at the first administration of leuprorelin; every 2 weeks thereafter up to week 12; and every 3 months thereafter. The observation period had to last for 2 years.
MATERIAL AND METHODS

ELIGIBILITY
All eligible patients underwent a baseline history taking and physical examination, a complete blood count, blood-chemistry studies, urinalysis, and measurement of PSA. These studies were conducted at baseline, at weeks 4, 8, and 12, and every 3 months thereafter. Patients underwent chest radiography, transrectal ultrasonography of the prostate, radionuclide bone scanning, and CT of the abdomen and pelvis at baseline and at 3, 12, and 24 months later.
Differences in the distributions of the background variables, and incidence, timing, frequency and severity of hot flashes were evaluated using χ2 or Mann-Whitney U tests. QOL scores for the various domains are shown as the mean ± SD, with a higher score always representing a better QOL. Repeated measure analyses of variance (ANOVA) were used to compare QOL scores between treatment groups. All P values reported are two-tailed, and P < 0.05 was considered significant.
RESULTS
In the present study 151 patients with prostate cancer were registered, 76 and 75 of whom were assigned to the chlormadinone and bicalutamide groups, respectively. Among them, there were 11 patients who were found to be ineligible after enrollment and 2 patients who refused treatment after assignment. Moreover, no data were reported after randomization in 14 patients. After removing these patients, a total of 124 patients, that is, 60 in the chlormadinone group and 64 in the bicalutamide group, were subject to analyses. No statistically significant difference was found in the background variables between the two groups ( Table 1) .
A significant difference was found in the timing of hot flashes between the two groups (P < 0.001, Table 2 ). Patients in the chlormadinone group experienced both warmth/flushing and sweating more often during sleep, whereas patients in the bicalutamide group experienced these symptoms more often when feeling tension. The median frequency of sweating was significantly lower in the chlormadinone group than in the bicalutamide group (1.0 vs. 3.6 episodes/day, respectively, P = 0.021), although there was no significant difference in the frequency of warmth/flushing between the two groups (1.3 vs. 2.2 episodes/day, respectively, P = 0.16, Table   2 ). A significant difference was found between the two groups with respect to the level of discontent about warmth/flushing (P < 0.001) and sweating (P = 0.027, Table 2 ). The percentage of patients who felt some discontent throughout the treatment period (all patients except those who gave a reply of "unanxious" and hot flash-free patients) based on the cumulated number of replies yielded the following values: for warmth/flushing, 8.2% in the chlormadinone group and 16.1% in the bicalutamide group; for sweating, 8.2% in the chlormadinone group and 12.7% in the bicalutamide group. Therefore, the discontent levels were significantly lower in the chlormadinone group (for warmth/flushing, odds ratio: 0.47 and P < 0.001; and for sweating, odds ratio: 0.61 and P = 0.01).
The incidences of warmth/flushing were lower in the chlormadinone group than in the bicalutamide group throughout the treatment period; significant differences were found at week 8 (P = 0.049), week 10 (P = 0.029), month 6 (P = 0.007) and month 9 (P = 0.023). The incidence of sweating was lower in the bicalutamide group at the early stage of treatment and in the chlormadinone group at week 10 or thereafter, but the difference was not statistically significant ( Fig. 1) . Also, there was no significant difference in the cumulative incidence of hot flashes at 2 years for warmth/flushing, 43.3% and 51.4% (P = 0.51) or for sweating, 51.7% and 48.5% (P = 0.80) in the chlormadinone and bicalutamide groups, respectively. The time-course changes in FACT-P total showed no changes of clinical relevance, and no significant difference was observed between the two groups. There were also no clinically significant time-course changes in any of the domains (Table 3 ).
Relapse occurred in six patients in the chlormadinone group and 10 in the bicalutamide group during the treatment period. Furthermore, there were four deaths (two from cancer and two from other causes of death) in the chlormadinone group and two deaths (one from cancer and one from another cause of death) in the bicalutamide group.
The major toxic effects rated grade 2 or higher except for hot flashes were hepatic dysfunction in eight patients (13.3%) in the chlormadinone group, and anemia in two (3.1%) and diarrhea in two (3.1%) in the bicalutamide group. Consequently administration of chlormadinone was discontinued due to hepatic dysfunction in five patients. After administration was discontinued, the hepatic function was normalized in all patients. On the other hand, administration of bicalutamide was discontinued due to diarrhea in two patients, which was followed by full recovery.
COMMENT
Many studies have reported decreased QOL in hormonal therapy, [8] [9] [10] [11] which is mostly considered attributable to androgen deprivation-induced side effects, e.g., hot flashes, sexual dysfunction, weight gain, muscle weakness, anemia, osteoporosis, depression and gynecomastia. Recently, hot flashes have elicited concern as a factor that lowers QOL. Charig et al. 9 reported that castration provoked hot flashes in 76% of patients, that one-third of them had severe hot flashes, and that the mean duration of disease was as long as 33 months. Furthermore, Carpenter et al. 10 used the SF-12 to evaluate QOL and reported that hot flashes tended to cause QOL to deteriorate in relation to mental health and physical function. However, all of these studies were conducted using a cross-sectional design. Therefore, Basaria et al. 8 indicated the need to conduct a longitudinal study in order to clarify the relationship between the timing/severity of adverse events and QOL.
In our prospective, randomized controlled study, the level of discontent about hot flashes was approximately twofold greater in the bicalutamide group than in the chlormadinone group. The difference in the number of episodes of hot flashes per day seemed to have affected the difference in level of discontent between the two groups. Therefore, hot flashes were shown to be a factor that lowers QOL. In consideration of the above arguments, the magnitude of a QOL decrease due to hot flashes was considered to be greater in the bicalutamide group than in the chlormadinone group. However, despite a significant difference between the two groups with respect to the severity of hot flashes, the time course of the FACT-P total and each of the domain scores showed no inter-group differences. Although hot flashes appear to reduce QOL, it is likely to be difficult to evaluate the degree of adverse effects due to hot flashes on QOL using the FACT-P questionnaire.
Although the pathophysiology of hot flashes remains unknown, a decline in sex hormone concentrations might lead to alterations in brain neurotransmitters and to instability in the hypothalamic thermoregulatory setpoint 1 . In the present study, although all patients were medically castrated, there were considerable differences in the clinical feature of hot flashes between the two treatment groups. Bicalutamide is a pure antiandrogen, whereas chlormadinone is a progestin with progestational as well as antiandrogenic properties, which might partly explain the clinical differences between the two antiandrogens. In fact, various studies have demonstrated that progestins can ameliorate hot flashes in menopausal women [12] [13] [14] and in men who have undergone ADT for prostate cancer. 4 Although the mechanism of action of progestins in controlling hot flashes is unknown, it has been reported that progesterone inhibits most warm-sensitive neurons directly or indirectly via local neuronal circuits in the preoptic area of the hypothalamus in male and female rats. 15 Although no significant difference was found between the two groups with respect to 2-year progression-free survival (data not shown), the effects of the combination with chlormadinone on survival rate should be evaluated in a study of longer duration that takes the following into account: 1) as described in one report 16 the survival rate differs between CAB with a steroidal antiandrogen and CAB with a nonsteroidal antiandrogen; and 2) from the viewpoint of safety, chlormadinone, not cyproterone, was developed as a therapeutic drug for prostate cancer in Japan.
Hot flashes impair the QOL of patients treated with ADT, and our results suggest that CAB using a steroidal antiandrogen may induce fewer and less distressing hot flashes than CAB with a nonsteroidal antiandrogen. Since the present study has a limited duration of 2 years, the difference in survival time between the treatment groups was not assessed. A combined assessment of quality and quantity of life over a longer period of time is needed in ADT for patients with prostate cancer. Longitudinal changes in the incidence of warmth/flushing (A) and sweating (B). The incidences of warmth/flushing were significantly lower in the chlormadinone group than in the bicalutamide group at week 8 (P = 0.049), week 10 (P = 0.029), month 6 (P = 0.007) and month 9 (P = 0.023). 
